OmniAb, Inc.
NASDAQ:OABIBiotechnology
+$0.16 today
- Market cap
- $740.97M
- Beta
- 1.15
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.42
Volume 1.22M
Average 0.67M
OABI EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
OmniAb, Inc.NASDAQ: OABI
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$1.7M, compared with -$13.56M a year earlier. Trailing-twelve-month EBITDA was -$33.82M.
Context
- EBITDA amounted to 238.6% of revenue in FY2025, up 57.4 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$16.52M (+62.9%) for the fiscal year ending Dec 2026, a step up from the +6.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$1.7M+75.1% QoQ
- Last fiscal yearDec 2025
- -$44.54M+6.9% YoY
- LTMMar 2026
- -$33.82M+24.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +87.5% | +43.9% | -43.5 pp |
| 1 year | +6.9% | +62.9% | +56.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (44.54M) USD
- Year-over-year change
- +6.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (44.54M) | +6.9% |
| FY2024 | 2024-12-31 | (47.83M) | -6.6% |
| FY2023 | 2023-12-31 | (44.87M) | -474.3% |
| FY2022 | 2022-12-31 | (7.81M) | +56.8% |
| FY2021 | 2021-12-31 | (18.09M) | — |
EBITDA vs competitors
How OABI compares with its peers on the latest reported figures
- OABI's LTM Mar 2026 EBITDA of -$33.82M is the highest of the 4 companies compared; the peer median is -$106.12M.
- Its year-over-year change of +24.4% is the 2nd highest of 4, against a peer median of -7.0%.
- EBITDA amounts to 117.0% of revenue for OABI, versus a peer median of 106.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$33.82M | +24.4% | — | 117.0% | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$106.12M | +42.0% | — | 106.5% | |
| LTM Mar 2026 | -$106.84M | -14.3% | — | 5818.9% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding OABI) | -$106.12M | -7.0% | — | 106.5% | |
Competitors are the stored peer set for OABI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 34.75M | 59.08M | 34.16M | 26.39M | 18.67M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 22.06M |
| Gross Profit | 34.75M | 59.08M | 34.16M | 26.39M | (3.39M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -18.2% |
| Research & Development | 39.23M | 48.36M | 56.53M | 55.11M | 47.75M |
| Selling, General & Admin | 16.95M | 24.9M | 33.31M | 30.74M | 29.22M |
| Operating Expenses | 70.36M | 85.73M | 103.58M | 100.89M | 68.13M |
| Depreciation & Amortization | 16.25M | 18.25M | 19.5M | 23.58M | 21.75M |
| EBITDA | (18.09M) | (7.81M) | (44.87M) | (47.83M) | (44.54M) |
| EBITDA Margin | -52.1% | -13.2% | -131.3% | -181.2% | -238.6% |
| Operating Income | (35.61M) | (26.65M) | (69.42M) | (74.5M) | (71.52M) |
| Operating Margin | -102.5% | -45.1% | -203.2% | -282.3% | -383.1% |
| Interest Income | 0 | 587K | 5.06M | 3.11M | 2.66M |
| Interest Expense | 7K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.26M | 587K | 5.06M | 3.09M | 5.22M |
| Income Before Tax | (34.35M) | (26.06M) | (64.36M) | (71.41M) | (66.29M) |
| Pre-Tax Margin | -98.9% | -44.1% | -188.4% | -270.6% | -355.2% |
| Income Tax Expense | (7.31M) | (3.73M) | (13.74M) | (9.38M) | (1.52M) |
| Net Income | (27.04M) | (22.33M) | (50.62M) | (62.03M) | (64.78M) |
| Net Margin | -77.8% | -37.8% | -148.2% | -235.1% | -347.0% |
| EPS (Basic) | (0.24) | (0.26) | (0.51) | (0.61) | (0.57) |
| EPS (Diluted) | (0.24) | (0.26) | (0.51) | (0.61) | (0.57) |
| Weighted Avg Shares | 114.82M | 85.32M | 99.68M | 102.37M | 113.64M |
| Weighted Avg Shares (Diluted) | 114.82M | 85.32M | 99.68M | 102.37M | 113.64M |
OmniAb, Inc.
NASDAQ:OABI
Intrinsic Alpha fair value
Locked
Current Price
$5.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.